文献速递消化、代谢与肾脏急症心脑血管急症

SGLT-2抑制剂与GLP-1受体激动剂治疗2型糖尿病:随机对照试验的系统评价与网络荟萃分析

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
PubMed 文献 · BMJ · 2021-01-13
一句话结论在2型糖尿病患者中,SGLT-2抑制剂和GLP-1受体激动剂均降低全因死亡、心血管死亡、非致死性心梗和肾衰竭,绝对获益随心血管/肾脏风险升高而增大。

该系统评价与网络荟萃分析纳入764项随机对照试验、共421 346例2型糖尿病患者,评估SGLT-2抑制剂或GLP-1受体激动剂与安慰剂、标准治疗或其他降糖治疗的比较。两种药物均降低全因死亡、心血管死亡、非致死性心肌梗死和肾衰竭(高确定性证据)。SGLT-2抑制剂更多减少心衰住院,GLP-1受体激动剂更多减少非致死性卒中;SGLT-2抑制剂引起生殖器感染(高确定性),GLP-1受体激动剂可能引起严重胃肠道事件(低确定性)。绝对获益随患者心血管和肾脏风险显著变化,如SGLT-2抑制剂在5年内每1000例患者减少3至40例死亡。

要点

  • 两种药物均降低全因死亡、心血管死亡、非致死性心梗和肾衰竭,证据确定性高,适用于2型糖尿病成人。
  • SGLT-2抑制剂降低心衰住院优于GLP-1受体激动剂;GLP-1受体激动剂降低非致死性卒中,SGLT-2抑制剂对卒中似无效果。
  • SGLT-2抑制剂引起生殖器感染(高确定性);GLP-1受体激动剂可能引起严重胃肠道事件(低确定性)。
  • 绝对获益随心血管/肾脏风险变化:SGLT-2抑制剂5年内每1000例减少3至40例死亡(极低危至极高危)。
  • 关于截肢、失明、眼病、神经病理性疼痛或健康相关生活质量,证据很少或没有。

适用人群与场景

  • 成人2型糖尿病患者,随访至少24周;纳入比较SGLT-2抑制剂或GLP-1受体激动剂与安慰剂、标准治疗或其他降糖治疗的随机对照试验。
  • 结果按心血管/肾脏风险分层:极低危(无心血管危险因素)、低危(≥3个心血管危险因素)、中危(心血管疾病)、高危(慢性肾脏病)、极高危(心血管疾病和肾脏病)。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 所有结果均指在现有糖尿病治疗基础上加用SGLT-2抑制剂或GLP-1受体激动剂,未提供具体药物剂量、给药途径或频次。
  • SGLT-2抑制剂和GLP-1受体激动剂均降低全因死亡、心血管死亡、非致死性心肌梗死和肾衰竭(高确定性证据)。

红旗征与不能漏的情况

  • SGLT-2抑制剂引起生殖器感染(高确定性证据),需警惕。
  • GLP-1受体激动剂可能引起严重胃肠道事件(低确定性证据),需关注。

研究设计与关键结果

  • 网络荟萃分析纳入764项随机对照试验、421 346例患者;所有结果均指在现有糖尿病治疗基础上加用SGLT-2抑制剂或GLP-1受体激动剂。
  • 两种药物均降低全因死亡、心血管死亡、非致死性心肌梗死和肾衰竭(高确定性证据)。
  • SGLT-2抑制剂降低心衰住院优于GLP-1受体激动剂;GLP-1受体激动剂降低非致死性卒中,SGLT-2抑制剂对卒中似无效果。
  • SGLT-2抑制剂引起生殖器感染(高确定性);GLP-1受体激动剂可能引起严重胃肠道事件(低确定性)。
  • 低确定性证据提示两种药物可能降低体重;关于截肢、失明、眼病、神经病理性疼痛或健康相关生活质量,证据很少或没有。
  • 绝对获益随风险变化:SGLT-2抑制剂5年内每1000例患者减少3至40例死亡(极低危至极高危)。

证据类型、等级与局限

  • 证据类型:系统评价与网络荟萃分析(随机对照试验),采用GRADE评估证据确定性。
  • 证据等级:全因死亡、心血管死亡、非致死性心肌梗死、肾衰竭、心衰住院(SGLT-2抑制剂)、生殖器感染(SGLT-2抑制剂)为高确定性;严重胃肠道事件(GLP-1受体激动剂)为低确定性;体重降低为低确定性。
  • 局限:原文未明确报告纳入研究的偏倚风险细节、异质性或网络一致性信息;部分结局证据很少或没有。

对床旁实践的改变

  • 对于2型糖尿病成人,在现有降糖治疗基础上加用SGLT-2抑制剂或GLP-1受体激动剂可降低全因死亡、心血管死亡、非致死性心梗和肾衰竭,绝对获益随患者心血管/肾脏风险升高而增大。
  • 心衰住院风险较高的患者可能优先考虑SGLT-2抑制剂;卒中风险较高的患者可能优先考虑GLP-1受体激动剂。
  • 使用SGLT-2抑制剂需警惕生殖器感染;使用GLP-1受体激动剂需关注严重胃肠道事件(低确定性)。
  • 对于截肢、失明、眼病、神经病理性疼痛或健康相关生活质量,现有证据不足以指导决策。

指南或共识出处

  • BMJ Rapid Recommendations(直接基于本系统评价)
  • PROSPERO注册号CRD42019153180

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying cardiovascular and renal risk.

DESIGN: Network meta-analysis.

DATA SOURCES: Medline, Embase, and Cochrane CENTRAL up to 11 August 2020.

ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials comparing SGLT-2 inhibitors or GLP-1 receptor agonists with placebo, standard care, or other glucose lowering treatment in adults with type 2 diabetes with follow up of 24 weeks or longer. Studies were screened independently by two reviewers for eligibility, extracted data, and assessed risk of bias.

MAIN OUTCOME MEASURES: Frequentist random effects network meta-analysis was carried out and GRADE (grading of recommendations assessment, development, and evaluation) used to assess evidence certainty. Results included estimated absolute effects of treatment per 1000 patients treated for five years for patients at very low risk (no cardiovascular risk factors), low risk (three or more cardiovascular risk factors), moderate risk (cardiovascular disease), high risk (chronic kidney disease), and very high risk (cardiovascular disease and kidney disease). A guideline panel provided oversight of the systematic review.

RESULTS: 764 trials including 421 346 patients proved eligible. All results refer to the addition of SGLT-2 inhibitors and GLP-1 receptor agonists to existing diabetes treatment. Both classes of drugs lowered all cause mortality, cardiovascular mortality, non-fatal myocardial infarction, and kidney failure (high certainty evidence). Notable differences were found between the two agents: SGLT-2 inhibitors reduced admission to hospital for heart failure more than GLP-1 receptor agonists, and GLP-1 receptor agonists reduced non-fatal stroke more than SGLT-2 inhibitors (which appeared to have no effect). SGLT-2 inhibitors caused genital infection (high certainty), whereas GLP-1 receptor agonists might cause severe gastrointestinal events (low certainty). Low certainty evidence suggested that SGLT-2 inhibitors and GLP-1 receptor agonists might lower body weight. Little or no evidence was found for the effect of SGLT-2 inhibitors or GLP-1 receptor agonists on limb amputation, blindness, eye disease, neuropathic pain, or health related quality of life. The absolute benefits of these drugs vary substantially across patients from low to very high risk of cardiovascular and renal outcomes (eg, SGLT-2 inhibitors resulted in 3 to 40 fewer deaths in 1000 patients over five years; see interactive decision support tool (https://magicevidence.org/match-it/200820dist/#!/) for all outcomes.

CONCLUSIONS: In patients with type 2 diabetes, SGLT-2 inhibitors and GLP-1 receptor agonists reduced cardiovascular and renal outcomes, with some differences in benefits and harms. Absolute benefits are determined by individual risk profiles of patients, with clear implications for clinical practice, as reflected in the BMJ Rapid Recommendations directly informed by this systematic review.

SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42019153180.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021. PMID: 33441402. doi:10.1136/bmj.m4573

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。